Topical treatment of BCC with forskolin decreases tumor growth and reduces GLI1 mRNA level in an inducible SMO-mutant BCC mouse model, providing evidence that forskolin inhibits growth of BCCs resistant to SMO inhibitors [161]. The gene discussed is GLI1; the disease is skin basal cell carcinoma.